Similar articles

Abstract: Objective: To evaluate the inhibitory role of a novel oncolytic adenovirus (OA), GP73-SphK1sR-Ad5, on the growth of hepatocellular carcinoma (HCC). Methods: GP73-SphK1sR-Ad5 was constructed by integrating golgi protein 73 (GP73) promoter and sphingosine kinase 1 (SphK1)-short hairpin RNA (shRNA) into adenovirus serotype 5 (Ad5), and transfecting into HCC Huh7 cells and normal human liver HL-7702 cells. The expression of SphK1 and adenovirus early region 1 (E1A) was detected by quantitative real-time PCR (qRT-PCR) and western blot, respectively. Cell viability was detected by methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay, and apoptotic rate was determined by flow cytometry. An Huh7 xenograft model was established in mice injected intratumorally with GP73-SphK1sR-Ad5. Twenty days after injection, the tumor volume and weight, and the survival time of the mice were recorded. The histopathological changes in tumor tissues were observed by hematoxylin-eosin (HE) staining and transmission electron microscopy (TEM). Results: Transfection of GP73-SphK1sR-Ad5 significantly upregulated E1A and downregulated SphK1 in Huh7 cells, but not in HL7702 cells. GP73-SphK1sR-Ad5 transfection significantly decreased the viability and increased the apoptotic rate of Huh7 cells, but had no effect on HL7702 cells. Intratumoral injection of GP73-SphK1sR-Ad5 into the Huh7 xenograft mouse model significantly decreased tumor volume and weight, and prolonged survival time. It also significantly decreased the tumor infiltration area and blood vessel density, and increased the percentages of cells with nucleus deformation and cells with condensed chromatin in tumor tissues. Conclusions: GP73-SphK1sR-Ad5 serves as a novel OA and can inhibit HCC progression with high specificity and efficacy.

一种新的溶瘤腺病毒抑制肝癌细胞的生长

[1]Baker AT, Aguirre-Hernández C, Halldén G, et al., 2018. Designer oncolytic adenovirus: coming of age. Cancers, 10(6):201.

[2]Bao MY, Chen ZA, Xu YF, et al., 2012. Sphingosine kinase 1 promotes tumour cell migration and invasion via the S1P/EDG1 axis in hepatocellular carcinoma. Liver Int, 32(2):331-338.

[3]Bao YH, Guo YC, Zhang CL, et al., 2017. Sphingosine kinase 1 and sphingosine-1-phosphate signaling in colorectal cancer. Int J Mol Sci, 18(10):2109.

[4]Chen W, Wu YQ, Liu W, et al., 2011. Enhanced antitumor efficacy of a novel fiber chimeric oncolytic adenovirus expressing p53 on hepatocellular carcinoma. Cancer Lett, 307(1):93-103.

[5]Choi JW, Lee JS, Kim SW, et al., 2012. Evolution of oncolytic adenovirus for cancer treatment. Adv Drug Deliv Rev, 64(8):720-729.

[6]Cuvillier O, 2007. Sphingosine kinase-1—a potential therapeutic target in cancer. Anti-Cancer Drugs, 18(2):105-110.

[7]Dai SD, Takabe K, Kapitonov D, et al., 2008. Targeting SphK1 as a new strategy against cancer. Curr Drug Targets, 9(8):662-673.

[8]Datta A, Loo SY, Huang BH, et al., 2014. SPHK1 regulates proliferation and survival responses in triple-negative breast cancer. Oncotarget, 5(15):5920-5933.

[9]https://doi.org/10.18632/oncotarget.1874

[10]Dong M, Chen ZH, Li X, et al., 2017. Serum Golgi protein 73 is a prognostic rather than diagnostic marker in hepatocellular carcinoma. Oncol Lett, 14(5):6277-6284.

[11]Fang T, Dong YH, Zhang XM, et al., 2016. Integrating a novel SN38 prodrug into the PEGylated liposomal system as a robust platform for efficient cancer therapy in solid tumors. Int J Pharm, 512(1):39-48.

[12]Guan HY, Liu LH, Cai JC, et al., 2011. Sphingosine kinase 1 is overexpressed and promotes proliferation in human thyroid cancer. Mol Endocrinol, 25(11):1858-1866.

[13]He GQ, Lei W, Wang SB, et al., 2012. Overexpression of tumor suppressor TSLC1 by a survivin-regulated oncolytic adenovirus significantly inhibits hepatocellular carcinoma growth. J Cancer Res Clin Oncol, 138(4):657-670.

[14]Kalogeridi MA, Zygogianni A, Kyrgias G, et al., 2015. Role of radiotherapy in the management of hepatocellular carcinoma: a systematic review. World J Hepatol, 7(1):101-112.

[15]Kawamori T, Osta W, Johnson KR, et al., 2006. Sphingosine kinase 1 is up-regulated in colon carcinogenesis. FASEB J, 20(2):386-388.

[16]Kurihara T, Brough DE, Kovesdi I, et al., 2000. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest, 106(6):763-771.

[17]Kwon OJ, Kim PH, Huyn S, et al., 2010. A hypoxia- and α-fetoprotein-dependent oncolytic adenovirus exhibits specific killing of hepatocellular carcinomas. Clin Cancer Res, 16(24):6071-6082.

[18]Lamarca A, Mendiola M, Barriuso J, 2016. Hepatocellular carcinoma: exploring the impact of ethnicity on molecular biology. Crit Revin Oncol/Hematol, 105:65-72.

[19]Larson C, Oronsky B, Scicinski J, et al., 2015. Going viral: a review of replication-selective oncolytic adenoviruses. Oncotarget, 6(24):19976-19989.

[20]Liu H, Zhang CX, Ma Y, et al., 2016. SphK1 inhibitor SKI II inhibits the proliferation of human hepatoma HepG2 cells via the Wnt5a/β-catenin signaling pathway. Life Sci, 151: 23-29.

[21]Liu HY, Han BJ, Zhong YX, et al., 2009. A three-plasmid system for construction of armed oncolytic adenovirus. J Virol Methods, 162(1-2):8-13.

[22]Liu YM, Zhang XD, Sun T, et al., 2016. Knockdown of Golgi phosphoprotein 2 inhibits hepatocellular carcinoma cell proliferation and motility. Oncotarget, 7(16):21404-21415.

[23]Livak KJ, 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCT method. Methods, 25(4):402-408.

[24]Nguyen A, Ho L, Wan Y, 2014. Chemotherapy and oncolytic virotherapy: advanced tactics in the war against cancer. Front Oncol, 4:145.

[25]Pan J, Tao YF, Zhou Z, et al., 2011. An novel role of sphingosine kinase-1 (SPHK1) in the invasion and metastasis of esophageal carcinoma. J Transl Med, 9(1):157.

[26]Rinninella E, Cerrito L, Spinelli I, et al., 2017. Chemotherapy for hepatocellular carcinoma: current evidence and future perspectives. J Clin Transl Hepatol, 5(3):235-248.

[27]Singal AG, Nehra M, Adams-Huet B, et al., 2013. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol, 108(3):425-432.

[28]Small EJ, Carducci MA, Burke JM, et al., 2006. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther, 14(1):107-117.

[29]Wang HX, Chen JM, Xu C, et al., 2017a. Cancer nanomedicines stabilized by Π-Π stacking between heterodimeric prodrugs enable exceptionally high drug loading capacity and safer delivery of drug combinations. Theranostics, 7(15):3638-3652.

[30]Wang HX, Lu ZJ, Wang LJ, et al., 2017b. New generation nanomedicines constructed from self-assembling small-molecule prodrugs alleviate cancer drug toxicity. Cancer Res, 77(24):6963-6974.

[31]Wang HX, Zhou LQ, Xie K, et al., 2018. Polylactide-tethered prodrugs in polymeric nanoparticles as reliable nanomedicines for the efficient eradication of patient-derived hepatocellular carcinoma. Theranostics, 8(14):3949-3963.

[32]Wang LY, Zheng SS, 2018. Advances in predicting the prognosis of hepatocellular carcinoma recipients after liver transplantation. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 19(7):497-504.

[33]Wang YG, Liu T, Huang PP, et al., 2015. A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma. Oncotarget, 6(15):13564-13578.

[34]Wang ZD, Qu FY, Chen YY, et al., 2017. Involvement of microRNA-718, a new regulator of EGR3, in regulation of malignant phenotype of HCC cells. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 18(1):27-36.

[35]Wong J, Lee C, Zhang K, et al., 2012. Targeted oncolytic herpes simplex viruses for aggressive cancers. Curr Pharm Biotechnol, 13(9):1786-1794.

[36]Xie HY, Xu X, Chen JM, et al., 2016. Rational design of multifunctional small-molecule prodrugs for simultaneous suppression of cancer cell growth and metastasis in vitro and in vivo. Chem Commun (Camb), 52(32):5601-5604.

[37]Xu L, Xu SJ, Wang HX, et al., 2018. Enhancing the efficacy and safety of doxorubicin against hepatocellular carcinoma through a modular assembly approach: the combination of polymeric prodrug design, nanoparticle encapsulation, and cancer cell-specific drug targeting. ACS Appl Mater Interfaces, 10(4):3229-3240.

[38]Xu YZ, Dong BJ, Huang JW, et al., 2016. Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression. Oncotarget, 7(3):3233-3244.

[39]Yang J, Li JJ, Dai WQ, et al., 2015. Golgi protein 73 as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis. Exp Ther Med, 9(4):1413-1420.

[40]Yang L, Hu HL, Deng Y, et al., 2014. Role of SPHK1 regulates multi-drug resistance of small cell lung cancer and its clinical significance. Chin J Lung Cancer, 17(11):769-777 (in Chinese).

[41]Yang XD, Pan LH, Wang L, et al., 2015. Systematic review of single large and/or multinodular hepatocellular carcinoma: surgical resection improves survival. Asian Pac J Cancer Prev, 16(13):5541-5547.

[42]Zhang CX, Liu H, Gong YY, et al., 2014. Inhibitions of SphK1 inhibitor SKI II on cell cycle progression and cell invasion of hepatoma HepG2 cells. Acta Pharm Sin, 49(2):204-208 (in Chinese).

[43]Zhou Y, Yin X, Ying J, et al., 2012. Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis. BMC Cancer, 12:17.

[44]Zhu LM, Wang Z, Lin YX, et al., 2015. Sphingosine kinase 1 enhances the invasion and migration of non-small cell lung cancer cells via the AKT pathway. Oncol Rep, 33(3):1257-1263.